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Reirradiation practices for children with diffuse
intrinsic pontine glioma
  

Chantel Cacciotti, Kevin X. Liu, Daphne A. Haas-Kogan, and Katherine E. Warren
Dana Farber/Boston Children’s Cancer and Blood Disorder Center, Boston, Massachusetts (C.C., K.E.W.); Department
of Radiation-Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts (K.X.L.,
D.A.H.-K.).

Abstract
Background. Diffuse intrinsic pontine gliomas (DIPGs) are a leading cause of brain tumor deaths in children.
Current standard of care includes focal radiation therapy (RT). Despite clinical improvement in most patients, the
effect is temporary and median survival is less than 1 year. The use and benefit of reirradiation have been reported
in progressive DIPG, yet standardized approaches are lacking. We conducted a survey to assess reirradiation practices for DIPG in North America.
Methods. A 14-question REDCap survey was disseminated to 396 North American physicians who care for children
with CNS tumors.
Results. The response rate was 35%. Participants included radiation-oncologists (63%; 85/135) and pediatric oncologists/neuro-oncologists (37%; 50/135). Most physicians (62%) treated 1 to 5 DIPG patients per year, with 10%
treating more than 10 patients per year. Reirradiation was considered a treatment option by 88% of respondents.
Progressive disease and worsening clinical status were the most common reasons to consider reirradiation. The
majority (84%) surveyed considered reirradiation a minimum of 6 months following initial RT. Doses varied, with
median total dose of 2400 cGy (range, 1200-6000 cGy) and fraction size of 200 cGy (range, 100-900 cGy). Concurrent
use of systemic agents with reirradiation was considered in 46%, including targeted agents (37%), biologics (36%),
or immunotherapy (25%). One-time reirradiation was the most common practice (71%).
Conclusion. Although the vast majority of physicians consider reirradiation as a treatment for DIPG, total doses
and fractionation varied. Further clinical trials are needed to determine the optimal radiation dose and fractionation for reirradiation in children with progressive DIPG.
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A leading cause of death from CNS malignancies in children
is diffuse intrinsic pontine gliomas (DIPGs). These are aggressive tumors that represent 75% to 80% of pediatric brainstem
tumors and 10% of all childhood CNS tumors.1–3 The prognosis
for children with DIPGs is significantly worse than other brainstem tumors and other malignant gliomas given their location
because the pons contains vital structures critical for lifesustaining functions such as breathing, blood pressure, and
heart rate.3 Despite numerous clinical trials of chemotherapy

and biological response modifiers, median survival remains
less than 1 year from diagnosis.1–6 No efficacious treatment
exists for recurrent/progressive disease following radiotherapy,
and time to death after recurrence is approximately 3 months.7
Various treatment approaches, including reirradiation and systemic agents, are used with no standard of care for these patients in the refractory and recurrent setting.
Radiotherapy serves as the only treatment modality that
has been shown to lengthen survival after diagnosis with
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Methods

Results
The overall response rate was 35%. Two participants
were excluded because they did not treat DIPG patients.
Participants included radiation-oncologists (63%; 85/135)
and pediatric oncologist/pediatric neuro-oncologists (37%;
50/135).
Most physicians (62%) surveyed treated 1 to 5 DIPG patients per year, 24% treated 6 to 10 DIPG patients per year,
and 10% treated more than 10 patients per year. Most respondents (55%) practice at institutions that treat greater
than 50 new pediatric neuro-oncology patients annually
(Table 1). Four radiation oncologists and one pediatric
neuro-oncologist/pediatric oncologist did not respond to
this question.
Reirradiation was considered a potential treatment option by 88% of respondents, 85% (69/81) of radiation oncologists, and 94% (46/49) of pediatric neuro-oncologist/
oncologists. Worsening clinical status and progressive
disease were the most common reasons to consider
reirradiation. Responses were relatively similar among the
  

Table 1.

Number of New Pediatric Neuro-Oncology Patients Seen in Consultation per Year
0-25 new patients, % (n)

26-50 new patients, % (n)

51-75 new patients, % (n)

76-100 new patients, % (n)

> 100 new
patients,
% (n)

All respondents

30 (41)

14%(19)

15 (20)

11 (15)

29 (39)

Radiation oncologist

41 (35)

19 (16)

14 (12)

7 (6)

18 (15)

Pediatric neuro-oncologist/pediatric
oncologist

12 (6)

6 (3)

16 (8)

18 (9)

48 (24)
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A 14-question REDCap13 survey (Supplemental Table 1) regarding reirradiation practices was developed by pediatric
neuro-oncologists and radiation oncologists and emailed
to 396 North American physicians identified through an
International Pediatric Neuro-Oncology and RadiationOncology database. Pediatric oncologists/pediatric neurooncologists were included because they often serve as
patients’ primary physicians and follow patients with DIPG,
prescribe systemic adjuvant therapy, and refer patients to
radiation oncologists at the time of diagnosis for initial radiation along with at time of recurrence/progression for
consideration of reirradiation. Survey responses were collected and analyzed with descriptive statistics. Data were
analyzed using t tests and chi-square tests, as appropriate.

physician specialties, with 67% of radiation oncologists and
78% pediatric neuro-oncologists/oncologists considering
worsening clinical status as an indication and 65% and 66%
considering progressive disease or tumor growth, respectively. Other considerations for reirradiation included patients’ initial response to radiotherapy. Contraindications
to reirradiation included poor performance status (70%),
size of the tumor (18%), edema on imaging (8%), and steroid dependency (11%) (Figure 1A). Additional reasons
for not considering reirradiation included short interval to
progression, evidence of radiation necrosis, sedation requirements of the child, poor/no clinical response to initial
radiotherapy, and intratumoral hemorrhage.
The majority (84%) surveyed considered reirradiation a
minimum of 6 months following initial radiotherapy, with
none suggesting reirradiation less than 3 months from
initial radiotherapy (Figure 1B). A small number of participants (12%) would not consider reirradiation, and 3 radiation oncologists did not answer this question.
Photon radiotherapy for reirradiation in DIPG was considered by 98% of respondents, whereas 18% would consider treatment with proton reirradiation. Notably, all
radiation oncologists answered this question, whereas
28% (14/50) of medical oncologists did not provide an answer. Although all physicians, regardless of their specialty,
were asked about radiation doses administered, of those
physicians that considered reirradiation, only 44% (22/50)
of the pediatric oncologists/pediatric neuro-oncologists
specified doses used; all others indicated radiation dosing
was determined by their radiation oncologists. All radiation oncologists who considered reirradiation responded
to this question with a specified dose. Although radiation
therapy (RT) doses varied with a median total dose of 2400
cGy (range, 1200-6000 cGy) (Figure 2A) and median dose
per fraction of 200 cGy (range, 100-900 cGy) (Figure 2B),
most respondents (87%) recommended a total dose between 2000 and 3600 cGy, regardless of specialty, and 91%
considered a fractionation regimen with 180 to 300 cGy/
fraction. One radiation oncologist considered focal stereotactic radiosurgery/radiotherapy with 3000 to 4500 cGy in 1
to 5 fractions, and another would consider 5040 cGy in 120cGy twice-daily fractions. One-time reirradiation was the
most common practice (71%) (66% among radiation oncologists and 70% among pediatric oncologists), whereas
18% overall (15% of radiation oncologists, 18% of medical
oncologists) would consider reirradiation twice and 5%
(4% of radiation oncologists and 6% of medical oncologists) more than 2 times. Interestingly, 12% of all respondents would not consider reirradiation, specifically 15%
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DIPG.8,9 With increasing evidence of its safety in pediatric CNS tumors, reirradiation is more frequently being
used for children with recurrent/progressive DIPG.10–12
Because standard reirradiation approaches are lacking,
we conducted a survey to characterize physician practice
patterns regarding reirradiation at time of DIPG recurrence or progression.
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Figure 1. Reirradiation practices. A, Contraindications to reirradiation: Contraindications included size of tumor (18%), poor performance status
(70%), edema on imaging (8%), and steroid dependency (11%). Other reasons included short interval to progression, evidence of radiation therapy
necrosis, sedation requirements in the child, poor/no clinical response to initial radiotherapy, and intratumoral hemorrhage. B, Time from initial
radiation to reirradiation: C, Concurrent therapy used with reirradiation: Concurrent use of systemic agents with reirradiation was considered in
46% of respondents, with targeted agents (37%), biologics (34%), immunotherapy (25%), intravenous chemotherapy (19%), and intrathecal chemotherapy (4%). D, Complications with reirradiation: Complications seen with reirradiation included asymptomatic necrosis (43%), symptomatic
necrosis (30%), and bleeding (9%). Other reasons included edema and steroid dependency.
  

of radiation oncologists and 6% of pediatric oncologists/
neuro-oncologists would not reirradiate a DIPG patient.
Concurrent use of systemic agents with reirradiation
was considered in 46% of respondents (47% of radiation
oncologists and 42% of pediatric oncologists/pediatric
neuro-oncologists), mainly with targeted agents (37%),
or immunotherapy (25%). Less commonly, intravenous
cytotoxic chemotherapy (19%) and intrathecal chemotherapy (4%) were also considered. Eleven participants,
all radiation oncologists, chose not to respond to this
question, whereas all pediatric oncologists/pediatric
neuro-oncologists responded. Of those that responded,
the use of adjuvant therapy did not differ between radiation oncologists or pediatric oncologists/pediatric
neuro-oncologists, with the exception of immunotherapy
being more frequently used by pediatric oncologists/pediatric neuro-oncologists. Interestingly, 23% (17/74) of
radiation oncologists and 14% (7/50) of pediatric oncologists/pediatric neuro-oncologists considered intravenous
chemotherapy, whereas intrathecal chemotherapy was
considered in 5% (4/74) and 2% (1/50), targeted agents
or biologics in 36% (27/74) and 38% (19/50), and immunotherapy in 31% (23/74) and 58% (29/50) (P = .003), of
radiation oncologists and pediatric oncologists/pediatric
neuro-oncologists, respectively (Figure 1C).
Of the respondents who have performed reirradiation,
42% reported reirradiation was well tolerated without any

complications. Of the complications experienced with
reirradiation, 43% of respondents noted asymptomatic
necrosis and 30% reported symptomatic necrosis. Less
common side effects included bleeding and edema and
steroid dependency (Figure 1D).

Discussion
RT remains an essential component of treatment for
many pediatric CNS tumors, including DIPG. Reirradiation
has been safely used in the treatment of recurrent
ependymomas and medulloblastomas with survival benefit and has been shown to be a safe approach in progressive DIPG that may prolong survival, although no
randomized phase 2 study has been conducted.7,10,12
Lack of consistency exists with reirradiation practices.
Despite most radiation oncologists and pediatric neurooncologists/pediatric oncologists considering 2000 to
3600 cGy reirradiation as a treatment option, the number
of times one would reirradiate, the use of systemic agents
along with reirradiation, and the indications or contraindications to such a treatment differed. This survey illustrates
the discrepancy among CNS tumor providers in the management of recurrent or progressive DIPG and further supports the need for standardized approaches.
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Figure 2. Reirradiation dosing. A, Total reirradiation dose for diffuse intrinsic pontine glioma (DIPG) patients based on physician responses:
Radiation therapy doses varied, with median total dose of 2400 cGy (range, 1200-6000 cGy). B, Dose per fraction of reirradiation in DIPG based on
physician responses: Median dose per fraction was 200 cGy (range, 100-900 cGy).
  

A few groups have retrospectively investigated outcomes of a relatively small cohort of recurrent/progressive DIPG patients treated with reirradiation (Table 2). The
University of Texas MD Anderson Cancer Center treated 5
patients with reirradiation using 1800 cGy in 10 fractions
(1 patient) or 2000 cGy in 10 fractions (4 patients) along
with concurrent chemotherapy in second or subsequent
progressive DIPG. The patients in this cohort tolerated
reirradiation well, with minimal adverse events, none of
which were greater than grade 2 toxicities. The median
time to progression was 5 months.14 An Italian group used
reirradiation along with nimotuzumab and vinorelbine
in a phase 2 trial for newly diagnosed DIPG patients;
reirradiation was employed at progression. Twenty patients were noted to have progressive disease, of whom 16
had local progression. Eleven patients were treated with
focal reirradiation (1980 cGy in 180-cGy daily fractions).
Of the 5 patients with disseminated disease, 4 underwent

focal reirradiation to the primary as well as metastatic
sites of disease. This approach was well tolerated without
any unexpected adverse effects or decline in neurological
status. The median survival was 6 months (range, 6 weeks14 months) following reirradiation.15,16 A retrospective
European review of DIPG cases included 31 patients who
were reirradiated at first progression with doses ranging
from 1800 cGy to 3000 cGy, and some of the patients received concurrent systemic therapy. Clinical improvement
was noted in 77% of the patients and no life-threatening
or fatal toxicities reported. The median survival in this
larger cohort was 6.4 months following reirradiation compared to 3 months in a historical cohort not treated with
reirradiation at time of progression.17 Another retrospective review was conducted that included 16 DIPG patients
in Canada treated with reirradiation at progression. Focal
reirradiation was administered in 14 patients at doses
of 2160 to 3600 cGy. Two patients received whole-brain
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Table 2.

Summary of Studies With 5 or More Patients Evaluating Reirradiation in DIPG
Population

No.

Median
time from
initial RT
to re-RT,
mo

Reirradiation
doses

Concurrent systemic therapy

Median survival post
re-RT

Conclusion

Fontanilla
et al (2012)14

Progressive
DIPG

5

12.5

18 Gy or 20
Gy (focal)

NA

5 mo

Reirradiation was
well tolerated
with minimal adverse events

25 at NR
diagnosis,
11
re-RT

19.8 Gy
(focal)

Nimotuzmab and vinorelabine

6 mo
(range,
6 wks-14
mo)

Combination of
Nimotuzmab/
vinorelabine was
well tolerated

Newly
Massimino
et al (2014)15,16 diagnosed
DIPG with
reirradiation
at
progression
Vanan and
Eisenstat
(2015)5

Progressive
DIPG

10

NR

21.6-36 Gy
Valproic acid (1), bevacizumab
(focal) or 30.6 (1), temozolomide (1)
Gy (WB)

9 mo
(range, 5-13
mo)

Neurological improvement noted
in all but one
re-RT patient

Janssens et al
(2017)17

Progressive
DIPG

31

NR

18-30 Gy
(focal)

Re-RT alone (16), re-RT combined with systemic agents
(15) including nimotuzumab/
vinorelbine (9), etoposide (1),
valproic acid + celecoxib (1),
sirolimus (2), valproic acid,
temsirolimus + irinotecan (1),
bevacizumab (1)

6.4 mo

Patients who respond to upfront
RT benefit from
re-RT

Lassaletta
et al (2017)7

Progressive
DIPG

16

13

21.6-36 Gy
(focal) or
30.6 Gy (WB)

Bevacizumab in one patient,
all other RT alone. Seven patients received chemotherapy
following reirradiation with
various agents including
temozolomide, valproic
acid, nimotuzumab and
bevacizumab

6.48 mo
(range, 3.813.3 mo)

Re-RT was safe
and feasible in
patients with
progressive
DIPG

Kline et al
(2018)6

Progressive
DIPG

31,
re-RT
in 12

11.8

24 Gy (focal)

Nivolumab and re-RT (8)

6.8 mo
(re-RT with
nivolumab);
6.0 mo (reRT alone)

Re-RT with
concurrent PD-1
inhibition was
tolerated and
may offer survival benefit in
recurrent DIPG

Amsbaugh
et al (2019)18

Progressive
DIPG

12

12.3

24-30.8 Gy
(focal)

NA

5.8 mo

Re-RT is safe
and demonstrated clinical
improvement

Abbreviations: DIPG, diffuse intrinsic pontine glioma; NA, not applicable; NR, not reported; PD-1, programmed death-1; re-RT, reirradiation; RT,
radiation; WB, whole brain.
  

reirradiation (3060 cGy) because of disseminated disease. The median time from diagnosis to progression
was 10.5 months (range, 4-37 months). One patient received a third course of RT 6 months after reirradiation at
a dose of 2160 cGy. One patient received concurrent systemic therapy with bevacizumab; all others were treated
with radiotherapy alone. Seven patients received chemotherapy following reirradiation with various agents including temozolomide, valproic acid, nimotuzumab, and
bevacizumab. Reirradiation was well tolerated in all patients, with the exception of one patient who experienced
pontine necrosis progressing to cerebellar dysfunction and
quadriparesis after 3000 cGy in 10 fractions. Steroids were

avoided in 6 patients and discontinued in 4 patients by the
end of reirradiation in this cohort. Median survival post
reirradiation was 6.48 months (range, 3.8-13.3 months)
compared to 3 months (range, 3.8-13.9 months) in historical cohorts of 46 patients with progressive DIPG not
treated with reirradiation.7
Recently a prospective phase 1/2 trial investigated DIPG
reirradiation safe dosing using 3 efficacy domains: imaging assessment, clinical symptoms, and patient- or
family-reported quality of life.18 Patients had a median
of 12.3 months from initial radiotherapy to reirradiation,
suggesting that these may be a more favorable cohort of
patients because most patients recur earlier. Six patients
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Conclusion
DIPG, which accounts for 10% to 20% of all childhood brain
tumors, continues to have a grim outcome, leading to devastating and debilitating neurological symptoms and an
overall survival of approximately 1 year from diagnosis.
Only RT has been shown to improve overall survival. As
research continues to investigate novel treatment options,
reirradiation may also be considered. Prior studies demonstrated a median survival of 5 to 7 months following
reirradiation, although prospective randomized phase 2
studies are lacking and no standard exists. Although considered a safe and feasible therapeutic option by practitioners caring for these patients, the doses of reirradiation,
indications and contraindications for reirradiation, and use
of adjuvant systemic therapy considered by oncologists in
this North American survey varied. Future clinical trials of
reirradiation to assess optimal dose, fractionation, interval
between radiotherapy, and the concurrent use of systemic
agents are necessary.

Supplementary material
Supplementary material is available online at NeuroOncology Practice (http://nop.oxfordjournals.org/).
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are needed to identify more standardized approaches to
reirradiation, including contraindications to treatment.
The timing from initial radiotherapy to reirradiation also
varies, with some patients treated as early as 3 months
after completion of RT in the European experience. In
those surveyed, 84% considered reirradiation a minimum
of 6 months following initial RT, with none considering
reirradiation less than 3 months from initial radiotherapy.
Further investigations are also needed to determine the
timing of reirradiation and whether there is an increased
risk to reirradiation within 6 months.
Several limitations of this study are acknowledged. As
an emailed survey, this study is restricted by those respondents that completed the questionnaire. Given that
an overall response rate of 35% was obtained, although
consistent with other survey response rates, the study is
limited by selection bias and sample size. As producers of
a survey-based study, we are limited by the options and
answers, thus further details surrounding the modality of
radiation (proton vs photon), contraindications, or indications to reirradiation could not be provided. All responses
were anonymous; thus, we are unable to comment on geographical practices or confirm/validate responses based
on institutional size. However, we acknowledge the anonymous responses may show differing responses among
providers at the same institution, which may be of interest
in future studies to better understand how management
decisions are made when there are conflicting opinions
about the course of action at the time of DIPG recurrence/
progression.

Neuro-Oncology
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received 2400 cGy in 12 fractions with improvement
in at least 2 of 3 efficacy domains. Of the 4 patients receiving 2640 cGy in 12 fractions, 2 patients demonstrated
improvement in at least 2 of 3 efficacy domains. Two patients received 3080 cGy in 14 fractions, and one patient
experienced grade 3 toxicity. Treatment was well tolerated, with no other reported toxicity (grade ≥ 3). From
start of reirradiation, median progression-free survival
and overall survival were 4.5 and 5.8 months, respectively. These findings suggest that 2400 cGy in 12 fractions
is safe and provides clinical benefit and improvement in
quality of life.18
Toxicities from reirradiation appear to be minimal, although existent, in the published literature.14,18 Commonly,
respondents noted necrosis (asymptomatic or symptomatic), edema, and steroid dependency. Despite these side
effects, 88% of those surveyed advocated reirradiation,
illustrating its possible beneficial role in palliative therapy.
In keeping with the results of previous studies, our
survey demonstrated that reirradiation is considered well
tolerated, with the majority of physicians treating with
photon irradiation at doses of 2000 to 3600 cGy. Further
prospective studies are needed to determine the optimal
dose and dose per fraction in the setting of reirradiation.
Worsening clinical status and progressive disease were
the most common reasons for considering reirradiation,
which also aligns with prior studies. In our cohort, a
larger portion of the pediatric oncologists/pediatric neurooncologists felt that worsening clinical status alone
warranted consideration of reirradiation compared to radiation oncologists. This may be attributed to the medical
oncology team serving as primary providers for these patients, monitoring their clinical status, and being more familiar with DIPG disease progression manifesting clinically
without radiographic progression.
The perceived benefit of reirradiation in children with
DIPG is difficult to assess. Most DIPG reirradiation studies
are retrospective or encompass a small cohort of patients,
and therefore indications for and contraindications to
reirradiation are difficult to assess. In previous phase 1 and
2 studies, timing from initial radiation, life expectancy of at
least 2 months, performance status (Lansky or Karnofsky
40 or higher), and no prior grade 3 or greater CNS toxicity
were considerations prior to reirradiating patients.15,18
These findings align with our survey results, with poor performance status serving as the most common reason for
avoiding reirradiation. We identified additional contraindications including size of tumor, tumor-associated edema
on imaging, steroid dependency, evidence of radiation necrosis, sedation requirements of the child, poor/no clinical
response to initial radiotherapy, and intratumoral hemorrhage. Although the survey did not capture more detailed
information surrounding these contraindications, the majority of respondents focused on aspects of safety of the
child, most encompassing potential complications or side
effects of further radiation. Steroid dependency was seen
as a contraindication in our study; further details were not
collected, but this may be due in part to worsening clinical
status and/or poorer perceived life expectancy, with the potential for further complications with reirradiation. Studies
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